# Vera H M Deneer

List of Publications by Year
in descending order



| 18 | 733 | 759233 12 | 794594 19 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 19 | 19 | 19 | 1071 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the geneâ€“drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). European Journal of Human Genetics, 2022, 30, 1105-1113. | 2.8 | 22 |
| 2 | Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. American Journal of Cardiovascular Drugs, 2022, 22, 195-206. | 2.2 | 13 |
| 3 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European Journal of Human Genetics, 2022, 30, 1114-1120. | 2.8 | 37 |
| 4 | The association between skeletal muscle measures and chemotherapyâ€induced toxicity in nonâ€small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1554-1564. | 7.3 | 18 |
| 5 | Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 9, 76-84. | 3.0 | 3 |
| 6 | Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. Journal of Personalized Medicine, 2021, 11, 1233. | 2.5 | 5 |
| 7 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the geneâ€“drug interaction of DPYD and fluoropyrimidines. European Journal of Human Genetics, 2020, 28, 508-517. | 2.8 | 127 |
| 8 | Genetic variants as predictors of toxicity and response in patients with nonâ€small cell lung cancer undergoing firstâ€line platinumâ€based chemotherapy: Design of the multicenter PGxLUNG study. Thoracic Cancer, 2020, 11, 3634-3640. | 1.9 | 5 |
| 9 | Effect of CYP3A4*22 and PPAR-Î± Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes, 2020, 11, 1068. | 2.4 | 2 |
| 10 | Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. Journal of Clinical Medicine, 2020, 9, 3249. | 2.4 | 5 |
| 11 | Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG). Circulation, 2020, 142, 1799-1807. | 1.6 | 37 |
| 12 | Association between serum biomarkers CEA and LDH and response in advanced nonâ€small cell lung cancer patients treated with platinumâ€based chemotherapy. Thoracic Cancer, 2020, 11, 1790-1800. | 1.9 | 20 |
| 13 | Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet, The, 2020, 395, 1374-1381. | 13.7 | 205 |
| 14 | Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Frontiers in Pharmacology, 2020, 11, 595219. | 3.5 | 103 |
| 15 | Pharmacogenetics of antitumor necrosis factor therapy in severe sarcoidosis. Current Opinion in Pulmonary Medicine, 2020, 26, 267-276. | 2.6 | 6 |
| 16 | Use of Pharmacogenetic Drugs by the Dutch Population. Frontiers in Genetics, 2019, 10, 567. | 2.3 | 32 |
| 17 | Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Clinical Pharmacology and Therapeutics, 2018, 103, 795-801. | 4.7 | 71 |
| 18 | Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. Pharmacogenomics, 2018, 19, 621-628. | 1.3 | 19 |